Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-229"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20081022.17.3-229"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-9892
lpv:speaker	lp:Edite Estrela2
lpv:spokenAs	vice-chair; FEMM (2007-02-01--2009-07-13)3 member; Delegation for relations with the countries of Central America (2007-03-14--2009-07-13)3 member; ENVI (2007-01-31--2009-07-13)3 member; PES (2004-07-20--2009-07-13)3 unknown; Partido Socialista (2004-07-20--2009-07-13)3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2007-05-23--2009-07-13)3 member; Temporary Committee on Climate Change (2007-05-10--2009-02-04)3 substitute; Delegation for relations with the People's Republic of China (2007-03-14--2009-07-13)3
lpv:translated text	". I voted in favour of Françoise Grossetête’s report on variations to the terms of marketing authorisations for medicinal products because I support a single licensing procedure for placing medicinal products on the Community market, as this will guarantee safety for European citizens. I must particularly highlight the proposal by the Socialist Group in the European Parliament on using the subsidiarity principle when applying the European variation system to medicinal products sold exclusively on the national market, thereby protecting small and medium-sized enterprises producing herbal medicines and homeopathic products."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph